Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,645 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,645 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00721981 | An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients… | — | terminated | Jul 25, 2008 | AstraZeneca | Low Recruitment | Enrollment / accrual |
| NCT00329472 | Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung… | Phase 3 | withdrawn | May 24, 2006 | Samsung Medical Center | poor enrollment | Enrollment / accrual |
| NCT00783471 | Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer…(DOPERLO) | Phase 2 | terminated | Oct 31, 2008 | Hellenic Cooperative Oncology Group | The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment… | Efficacy / futility |
| NCT00099879 | Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer | Phase 2 | terminated | Dec 22, 2004 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00359450 | Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non… | Phase 2 | terminated | Aug 2, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on… | Phase 1 | suspended | May 28, 2009 | Envita Medical Center, Inc. | not stated | Not stated |
| NCT00277329 | Study of XL999 in Patients With Non-small Cell Lung Cancer | Phase 2 | terminated | Jan 16, 2006 | Symphony Evolution, Inc. | Study was terminated due to cardiac toxicities in the subejcts | Safety / toxicity |
| NCT00491699 | Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer | Phase 1 | terminated | Jun 26, 2007 | Symphony Evolution, Inc. | The study was stopped due to safety concerns | Safety / toxicity |
| NCT01000896 | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and… | Phase 1 | withdrawn | Oct 23, 2009 | AstraZeneca | AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical… | Other (stated, no rule matched) |
| NCT00080509 | Effectiveness of KOS-862 in the Treatment of Lung Cancer | Phase 2 | terminated | Apr 7, 2004 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00473486 | Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and…(PECASO) | Phase 1 / Phase 2 | terminated | May 15, 2007 | University Hospital Muenster | Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance… | Other (stated, no rule matched) |
| NCT00378573 | Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by… | Phase 2 | terminated | Sep 20, 2006 | Sanofi | Incidence of GI Perforation | Other (stated, no rule matched) |
| NCT00264134 | Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Dec 12, 2005 | Kentuckiana Cancer Institute | not stated | Not stated |
| NCT00271323 | Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent… | Phase 2 | terminated | Dec 30, 2005 | Sanofi | not stated | Not stated |
| NCT00494026 | Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung… | Phase 2 | terminated | Jun 29, 2007 | Eli Lilly and Company | Study stopped early based on interim results of another trial, showing inferior activity of… | Other (stated, no rule matched) |
| NCT00447421 | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and… | Phase 1 / Phase 2 | terminated | Mar 14, 2007 | Eli Lilly and Company | Interim results of another trial showed inferior activity of treatment | Other (stated, no rule matched) |
| NCT00313768 | Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone… | Phase 2 | terminated | Apr 12, 2006 | Pfizer | See Termination Reason in Detailed Description. | Other (stated, no rule matched) |
| NCT00321308 | Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | May 3, 2006 | Pfizer | See Termination Reason in Detailed Description. | Other (stated, no rule matched) |
| NCT00273507 | Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and… | Phase 3 | terminated | Jan 9, 2006 | Rigshospitalet, Denmark | not stated | Not stated |
| NCT00461110 | A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell… | Phase 1 | terminated | Apr 17, 2007 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00434226 | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in… | Phase 2 | terminated | Feb 13, 2007 | Genentech, Inc. | Based on data collected, the combination appeared to be poorly tolearated. | Other (stated, no rule matched) |
| NCT00558922 | A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With… | Phase 1 / Phase 2 | terminated | Nov 15, 2007 | Aegera Therapeutics | Unacceptable Neurotoxicity (2 cases) | Other (stated, no rule matched) |
| NCT00532025 | Sorafenib in Resected Non-small Cell Lung Carcinoma(SIRN) | Phase 2 | terminated | Sep 19, 2007 | Johannes Gutenberg University Mainz | not stated | Not stated |
| NCT00234442 | Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | Phase 2 | terminated | Oct 7, 2005 | AstraZeneca | Closed due to insufficient recruitment. | Enrollment / accrual |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent…(FDG-PET lung) | Phase 3 | terminated | Aug 30, 2007 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT00383331 | Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell… | Phase 2 | terminated | Oct 3, 2006 | Eli Lilly and Company | Trial was stopped early due to low enrollment | Enrollment / accrual |
| NCT00259285 | Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer | Phase 2 | terminated | Nov 29, 2005 | Eli Lilly and Company | Trial was stopped early due to low enrollment. | Enrollment / accrual |
| NCT00475657 | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer | Phase 2 | terminated | May 21, 2007 | Eli Lilly and Company | Terminated due to lack of efficacy | Efficacy / futility |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell… | Phase 2 | terminated | Feb 15, 2007 | Threshold Pharmaceuticals | not stated | Not stated |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 15, 2005 | Pfizer | Terminated \[See Detailed Description for Termination Reason.\] | Other (stated, no rule matched) |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced… | Phase 1 | terminated | Jan 3, 2008 | Anza Therapeutics, Inc. | not stated | Not stated |
| NCT00161278 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC… | Phase 2 | terminated | Sep 12, 2005 | University of Michigan Rogel Cancer Center | recruitment has ended | Enrollment / accrual |
| NCT00535015 | Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small… | Phase 2 | terminated | Sep 26, 2007 | Anaborex | Objectives of study could not be met within a reasonable timeframe. | Other (stated, no rule matched) |
| NCT00607425 | Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening(SPIT-LC) | — | terminated | Feb 5, 2008 | Scottsdale Healthcare | Change in isolation method | Other (stated, no rule matched) |
| NCT00263016 | Docetaxel in Non Small Cell Lung Cancer (NSCLC) | Phase 2 | terminated | Dec 7, 2005 | Sanofi | Slow recruitment | Enrollment / accrual |
| NCT00098917 | Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II,… | Phase 1 | terminated | Dec 9, 2004 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT00215748 | Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel | Phase 2 | terminated | Sep 22, 2005 | Geriatric Oncology Consortium | slow accrual | Enrollment / accrual |
| NCT00061646 | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With… | Phase 2 | terminated | Jun 4, 2003 | Abbott | Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease… | Efficacy / futility |
| NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung… | Phase 3 | terminated | Oct 21, 2005 | Point Therapeutics | FDA Hold May 2007 | Other (stated, no rule matched) |
| NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung… | Phase 3 | terminated | Feb 10, 2006 | Point Therapeutics | FDA Hold May 2007 | Other (stated, no rule matched) |
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | Phase 2 | terminated | Apr 20, 2006 | Swedish Medical Center | not stated | Not stated |
| NCT00420862 | The DANTE Trial. A Randomized Study on Lung Cancer Screening With Low-Dose Spiral… | Phase 3 | terminated | Jan 11, 2007 | Istituto Clinico Humanitas | not stated | Not stated |
| NCT00179699 | Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To… | Phase 1 | terminated | Sep 16, 2005 | Celgene Corporation | not stated | Not stated |
| NCT00211952 | Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients | Phase 3 | suspended | Sep 21, 2005 | Medical University of Gdansk | not stated | Not stated |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced… | Phase 1 | terminated | Jul 11, 2003 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Dec 10, 2010source: clinicaltrials